Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Search results for: 'SARS-CoV-2'

Items 1721 - 1730 of 2690

Show
per page
  • 98.00%

    76.06 kDa (predicted); 99.1 kDa (reducing condition, due to glycosylation)

    SARS-CoV-2

    A DNA sequence encoding the SARS-CoV-2 (BF.7) Spike S1 (YP_009724390.1, with mutations T19I, 24-26del, A27S, 69-70del, G142D, V213G, G339D, R346T, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H) (Met1-Arg685) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant BF.7). Predicted N terminal: Val 16

    C-His

    100 μg
  • 98.00%

    136.42 kDa (predicted)

    SARS-CoV-2

    A DNA sequence encoding the SARS-CoV-2 (CH.1.1) Spike S1+S2 (YP_009724390.1, with mutations T19I, L24S, del25-27, G142D, K147E, W152R, F157L, I210V, V213G, G257S, G339H, R346T, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, K444T, G446S, L452R, N460K, S477N, T478K, E484A, F486S, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, F817P, A892P, A899P, A942P, Q954H, N969K, K986P, V987P and furin cleavage site mutants) expressed with the bacteriophage T4 fibritin and a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant CH.1.1). Predicted N terminal: Val 16

    C-His

    100 μg
  • 98.00%

    26.62 kDa (predicted); 35.15 kDa (reducing condition, due to glycosylation)

    SARS-CoV-2

    A DNA sequence encoding the SARS-CoV-2 (BA.4.6/BF.7) Spike RBD (YP_009724390.1, with mutation G339D, R346T, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant BA.4.6/BF.7). The purified protein was biotinylated in vitro. Predicted N terminal: Arg 319

    C-His

    20 μg
  • > 97 % by SDS-PAGE.

    Approximately 33.8 kDa, a single non-glycosylated polypeptide chain containing 306 amino acids.

    50 μg, 100 μg
  • > 90% by SDS-PAGE.

    Approximately 52.3 kDa as predicted, containing 465 amino acids. On SDS-PAGE, 54 kDa under reducing conditions, and 101.5 kDa as homodimer under non-reducing conditions.

    100 μg
  • > 90% by SDS-PAGE.

    Approximately 25.1 kDa, a single non-glycosylated polypeptide chain containing 223 amino acid residues.

    100 μg
  • 98.00%

    Human

    Gly21-Thr301(HLA-B*15:01), Ile21-Met119(B2M) and NQKLIANQF peptide

    C-His-Avi

    100 μg, 1 mg
  • 98.00%

    Human

    Gly21-Thr301(HLA-B*15:01), Ile21-Met119(B2M) and NQKLIANQF peptide

    C-His-Avi

    100 μg, 1 mg
  • 98.00%

    136.41 kDa (predicted)

    SARS-CoV-2

    A DNA sequence encoding the SARS-CoV-2 Spike S1+S2 (YP_009724390.1, with mutations T95I, Y144S, Y145N, R346K, E484K, N501Y, D614G, P681H, F817P, A892P, A899P, A942P, D950N, K986P, V987P and furin cleavage site mutants) expressed with the bacteriophage T4 fibritin and a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.621) which emerged in the South America. Predicted N terminal: Val 16

    C-His

    100 μg
  • 98.00%

    26.64 kDa (predicted); 32.78 kDa (reducing condition, due to glycosylation)

    SARS-CoV-2

    A DNA sequence encoding the SARS-CoV-2 Spike RBD (YP_009724390.1, with mutation L452R, T478R, E484Q) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus. The mutations were identified in the SARS-CoV-2 variant (known as variant B.1.630). Predicted N terminal: Arg 319

    C-His

    100 μg

Items 1721 - 1730 of 2690

Show
per page